Diasorin SpA (DSRLF) Stock Price, Trades & News

Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.

Financial Strength

6/10

Name	Current	Vs Industry
Cash-To-Debt	0.26
Equity-to-Asset	0.55
Debt-to-Equity	0.53
Debt-to-EBITDA	2.3
Interest Coverage	13.57
Piotroski F-Score	3/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.47	Distress Grey Safe
Beneish M-Score	-3.82	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

5/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-3.3
	3-Year EBITDA Growth Rate	-9.9
	3-Year EPS without NRI Growth Rate	-8.9
	3-Year FCF Growth Rate	-8.5
	3-Year Book Growth Rate	1.7
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	6.72
	Future 3-5Y Total Revenue Growth Rate Estimate	5.48

Momentum Rank

1/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	10.51
	9-Day RSI	28.47
	14-Day RSI	39.88
	3-1 Month Momentum %	10.22
	6-1 Month Momentum %	-2.88
	12-1 Month Momentum %	-31.42

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.55
	Quick Ratio	0.89
	Cash Ratio	0.41
	Days Inventory	296.59
	Days Sales Outstanding	62.94
	Days Payable	91.04

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	1.86
	Dividend Payout Ratio	0.38
	3-Year Dividend Growth Rate	4.6
	Forward Dividend Yield %	1.86
	5-Year Yield-on-Cost %	2.35
	3-Year Average Share Buyback Ratio	0.3
	Shareholder Yield %	13.88

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	64.66
	Operating Margin %	21.73
	Net Margin %	12.16
	EBITDA Margin %	29.4
	FCF Margin %	28.27
	OCF Margin %	28.27
	ROE %	9.02
	ROA %	4.71
	ROIC %	6.89
	3-Year ROIIC %	27.18
	ROC (Joel Greenblatt) %	47.63
	ROCE %	8.38
	Years of Profitability over Past 10-Year	10
	Moat Score	6

GF Value Rank

8/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	26.38
	Forward PE Ratio	18.09
	PE Ratio without NRI	22.08
	Shiller PE Ratio	19.47
	PS Ratio	3.48
	PB Ratio	2.56
	Price-to-Free-Cash-Flow	12.35
	Price-to-Operating-Cash-Flow	12.35
	EV-to-EBIT	19.27
	EV-to-Forward-EBIT	15.44
	EV-to-EBITDA	12.04
	EV-to-Forward-EBITDA	10.07
	EV-to-Revenue	3.55
	EV-to-Forward-Revenue	3.2
	EV-to-FCF	12.55
	Price-to-GF-Value	0.84
	Price-to-Projected-FCF	0.89
	Price-to-Median-PS-Value	0.57
	Earnings Yield (Greenblatt) %	5.19
	FCF Yield %	9.22
	Forward Rate of Return (Yacktman) %	7.39

Financials (Next Earnings Date:2026-07-31 Est.)

Annual Quarterly TTM

DSRLF's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with OTCPK:DSRLF

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Diasorin SpA Executives

Details

GF Value™: $95.96

DSRLF

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 4 Severe warning signs with DSRLF. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	1,359.183
	EPS (TTM) ($)	3.07
	Beta	0.2527
	3-Year Sharpe Ratio	-0.54
	3-Year Sortino Ratio	-0.65
	Volatility %	38.8
	14-Day RSI	39.88
	14-Day ATR ($)	0.749761
	20-Day SMA ($)	79.385
	12-1 Month Momentum %	-31.42
	52-Week Range ($)	66.5 - 107.68
	Shares Outstanding (Mil)	49.5

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	3
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Diasorin SpA Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Diasorin SpA Stock Events

Financials Calendars

Event	Date	Price ($)
Third quarter earnings conference call for 2026	2026-11-05 18:00	In 127 days
Third quarter earnings results for 2026	2026-11-05	In 126 days
Second quarter earnings conference call for 2026	2026-07-31 17:00	In 30 days
Second quarter earnings results for 2026	2026-07-31	In 29 days
EUR 1.300000 Cash Dividend	2026-05-18	67.00 (+0.00%)
First quarter earnings conference call for 2026	2026-05-08 18:00	67.00 (+0.00%)
First quarter earnings results for 2026	2026-05-08	67.00 (+0.00%)
General meeting for 2026	2026-04-29 15:00	71.94 (+0.00%)
Annual report for 2025	2026-04-02	67.00 (+0.00%)
Fourth quarter earnings conference call for 2025	2026-03-20 18:00	81.15 (+0.00%)

Show

Entries

Diasorin SpA Frequently Asked Questions

What is Diasorin SpA(DSRLF)'s stock price today?

The current price of DSRLF is $81.00. The 52 week high of DSRLF is $107.68 and 52 week low is $66.50.

When is next earnings date of Diasorin SpA(DSRLF)?

The next earnings date of Diasorin SpA(DSRLF) is 2026-07-31 Est..

Does Diasorin SpA(DSRLF) pay dividends? If so, how much?

The Dividend Yield % of Diasorin SpA(DSRLF) is 1.86% (As of Today), Highest Dividend Payout Ratio of Diasorin SpA(DSRLF) was 0.38. The lowest was 0.18. And the median was 0.3. The Forward Dividend Yield % of Diasorin SpA(DSRLF) is 1.86%. For more information regarding to dividend, please check our Dividend Page.

Guru Commentaries on OTCPK:DSRLF

No articles.

Press Release

	Subject	Date
	DiaSorin Obtains FDA Emergency Use Authorization and BARDA Funding for SARS-CoV-2 IgG Serology Kit for COVID-19 Testing in the U.S.	2020-04-25
	DiaSorin announces the launch of a fully automated serology test to detect antibodies against SARS-CoV-2 in COVID-19 patients by the end of April 2020, allowing identification of immune response development to the virus	2020-04-10

10/Page

Articles on Diasorin SpA

No articles.

Headlines

Jun 04, 2026

DiaSorin jumps amid takeover speculation

Seeking Alpha • 10:02am

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.